PURIBLOOD Business Summary

PURIBLOOD (6847.TWO) operates a high-margin medical technology business model centered on its proprietary Zwitterionic-bias Surface Coating (ZISC) technology, which enhances biocompatibility for blood cell separation and purification. The company generates revenue through the direct manufacture and sale of leukocyte reduction filters—positioning itself as Taiwan's sole domestic producer—and through the licensing of its anti-fouling composite materials (P-TEX) to industrial giants such as Nanya Technology and Formosa Plastics Group. Its primary business segments include blood transfusion safety, cell separation membranes, and advanced clinical filtration systems. In the global landscape, PURIBLOOD competes directly with specialized players like Medcura, ExThera Medical, and Lindis Blood Care; it distinguishes itself by offering "real-time" filtration that processes blood twice as fast as industry standards, facilitating its recent strategic expansion into the South American and European markets. The company was founded in 2016 by a team of academic and engineering experts, led by Professor Yung Chang, a distinguished professor at Chung Yuan Christian University (CYCU) and Director of the R&D Center for Membrane Technology. The current executive leadership is headed by Chairman and General Manager Chen Yan-Wen, who holds a Ph.D. in Chemical Engineering and oversees the firm's transition from a research-heavy startup to a commercial-scale manufacturer. Other key figures include co-founder and Vice President Dr. Ken Zhong, whose technical expertise in membrane science underpins the firm's 36+ patent portfolio. PURIBLOOD is backed by notable institutional investors, most significantly the CDIB Capital Group, which has been instrumental in funding the company's clinical trials and international distribution infrastructure.